Sumary of Tumor-Infiltrating Lymphocytes Provide ‘Viable Option’ for Advanced Melanoma:
- Rosenberg, MD, PhD, chief of the surgery branch and head of the tumor immunology section of NCI Center for Cancer Research, published the first report on the use of tumor-infiltrating lymphocytes (TILs) for the treatment of melanoma in 1988..
- Since then, this approach has remained relegated mostly to research facilities like the NIH and other large academic medical centers..
- Patients with melanoma who have disease progression after receiving immune checkpoint inhibitors have few options other than clinical trials, according to Warren A..
- Now, after 30-plus years in development, TILs soon may become commercially available for cancer treatment based on phase 1 and phase 2 trial results among patients with advanced melanoma..
- As one of the earliest forms of cancer immunotherapy, TILs may benefit from the clinical testing and regulatory approval trail blazed by chimeric antigen receptor T-cell therapy, the first gene-edited adoptive cell therapy approved for commercial use in the United States..
- “If approved, [TIL therapy] would be an option for approximately 10,000 [patients with] stage IV melanoma who die each year in the United States alone,”.
- Chesney, MD, PhD, director of James Graham Brown Cancer Center and associate vice president for health affairs at University of Louisville, told Cell Therapy Next..
- “Instead of going into hospice, receiving a palliative regimen of chemotherapy or another line of ineffective immunotherapy, this would be a viable option [from] which a significant proportion of patients would have a durable response.”…